A rapid, accurate test that can detect bio-markers of lung cancer in saliva is soon to be trialed in patients. The news marks a milestone in over 10 years of research led by oral cancer
and saliva diagnostics researcher Prof. David Wong, of the School of
Dentistry at the University of California-Los Angeles (UCLA) .Liquid biopsy holds the promise of rapid, less invasive identification of cancers and easier tracking of disease progress during treatment.
The device uses electric field-induced release and measurement (EFIRM) to detect non-small cell lung cancer (NSCLC) biomarkers in saliva.
The EFIRM device analyzes the contents of exosomes, tiny bags of
molecules that cells release now and again. The device forces the
exosomes to release their contents and carries out bio-recognition of
the released biomolecules at the same time.
The approach has a high accuracy compared with current sequencing
technology, says Prof. Wong, explaining that the trial in lung cancer
patients is taking place in China this year. The study is a
collaboration between UCLA and West China Hospital of Sichuan
University.
No comments:
Post a Comment